These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
2. FDA cancels plans requiring patient package inserts for drugs. Ob Gyn News; 1982 Mar 1-14; 17(5):5. PubMed ID: 11654881 [No Abstract] [Full Text] [Related]
3. A means to provide patient education: "Rx package inserts, patient package inserts, device labeling". Sherman M ONA J; 1979 Aug; 6(8):326-9. PubMed ID: 257297 [No Abstract] [Full Text] [Related]
4. Patient package inserts: the proper prescription? Rowe HM Food Drug Law J; 1995; 50(1):95-124. PubMed ID: 10342988 [No Abstract] [Full Text] [Related]
5. History of FDA patient package insert requirements. Am J Hosp Pharm; 1980 Dec; 37(12):1660-1. PubMed ID: 7004180 [No Abstract] [Full Text] [Related]
6. Prescription drugs; revocation of final guideline patient package inserts and withdrawal of draft guideline patient package inserts--Food and Drug Administration. Notice. Fed Regist; 1982 Sep; 47(173):39249-50. PubMed ID: 10258155 [TBL] [Abstract][Full Text] [Related]
7. The legal status of patient package inserts. Whitman JA Hosp Formul; 1978 Oct; 13(10):789-91. PubMed ID: 10238809 [No Abstract] [Full Text] [Related]
8. Prescription drug products that require patient package inserts; ampicillin and phenytoin--Food and Drug Administration. Final rule. Fed Regist; 1981 Jan; 46(1):28. PubMed ID: 10249520 [TBL] [Abstract][Full Text] [Related]
9. FDA proposes patient package inserts for most drugs. Mayberger HW; Bell BJ Leg Aspects Med Pract; 1979 Oct; 7(10):42-4. PubMed ID: 263192 [No Abstract] [Full Text] [Related]
10. Patient package inserts: goals versus achievements. Lasagna L Drug Ther; 1982; ():181-9. PubMed ID: 7105992 [No Abstract] [Full Text] [Related]
11. Patient package inserts: a research perspective. Morris LA; Groft SC Drug Ther; 1982; ():191-217. PubMed ID: 7105993 [No Abstract] [Full Text] [Related]
12. Informing patients about drugs: a wrong way and a right way. Woodson DW Med World News; 1979 Jun; 20(13):6. PubMed ID: 10242286 [No Abstract] [Full Text] [Related]
14. Progestational drug products for human use; requirements for labeling directed to the patient. Food and Drug Administration, HHS. Final rule. Fed Regist; 1999 Nov; 64(220):62110-2. PubMed ID: 11010691 [TBL] [Abstract][Full Text] [Related]
15. Educating patients about their medications: the potential and limitations of written drug information. Shrank WH; Avorn J Health Aff (Millwood); 2007; 26(3):731-40. PubMed ID: 17485751 [TBL] [Abstract][Full Text] [Related]
16. The federal preemption debate in pharmaceutical labeling product liability actions. Gross JM; Curry JA Tort Trial Insur Pract Law J; 2007; 43(1):35-70. PubMed ID: 18354866 [No Abstract] [Full Text] [Related]
17. Presumption of innocence: FDA's authority to regulate the specifics of prescription drug labeling and the preemption debate. Dorfman HL; Quinn VM; Brophy EA Food Drug Law J; 2006; 61(4):585-622. PubMed ID: 17180765 [No Abstract] [Full Text] [Related]
18. The new Food and Drug Administration drug package insert: implications for patient safety and clinical care. Watson KT; Barash PG Anesth Analg; 2009 Jan; 108(1):211-8. PubMed ID: 19095852 [TBL] [Abstract][Full Text] [Related]
19. The case for preemption of prescription drug failure-to-warn claims. Kim CH Food Drug Law J; 2007; 62(2):399-422. PubMed ID: 17632969 [No Abstract] [Full Text] [Related]
20. Institutional pharmacists' guide to complying with PPI regulations. Greenberg RB Am J Hosp Pharm; 1980 Dec; 37(12):1656-9. PubMed ID: 7446540 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]